18:36 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017...
19:03 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture studies suggest inhibiting PDE3A, FYB1, BICC1 or PURPL could help treat liver cancer. In two human liver cancer cell lines, shRNA targeting PDE3A, FYB1, BICC1 or PURPL decreased viability and...
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase 3A, bGMP-inhibited (PDE3A)

Cardiovascular disease INDICATION: Hypertension Genetic and in vitro studies suggest inhibiting PDE3A on vascular smooth muscle cells could help treat inherited hypertension and brachydactyly type E (HTNB). Whole-genome sequencing of 48 HTNB patients from 6...